PARC: A Phase I / II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in RElapsed/refractory Cancers of childhood

Mussai, Francis (Principal Investigator)
Beggs, Andrew (Co-Investigator)
Fenwick, Nicola (Co-Investigator)
Wheatley, Keith (Co-Investigator)
De Santo, Carmela (Co-Investigator)
Kearns, Pamela (Co-Investigator)
Slade, Daniel (Co-Investigator)

Short title	PARC: A Phase I / II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in RElapsed/refractory Cancers of childhood
Status	Finished
Effective start/end date	1/12/17 → 31/03/24

Funding

INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER (ITCC)
BIO-CANCER TREATMENT INTERNATIONAL LTD
Cancer Research UK

1 Article

PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults
Fenwick, N., Weston, R., Wheatley, K., Hodgson, J., Marshall, L., Elliott, M., Makin, G., Ng, A., Brennan, B., Lowis, S., Adamski, J., Kilday, J. P., Cox, R., Gattens, M., Moore, A., Trahair, T., Ronghe, M., Campbell, M., Campbell, H. & Williams, M. W. & 10 others, Kirby, M., Van Eijkelenburg, N., Keely, J., Scarpa, U., Stavrou, V., Fultang, L., Booth, S., Cheng, P., De Santo, C. & Mussai, F., 31 Jan 2024, In: Frontiers in Oncology. 14, 9 p., 1296576.
Research output: Contribution to journal › Article › peer-review

Open Access
File
68 Downloads (Pure)